Mingyan Pharma Completes Pre-A Funding Round, Offers CRO Services Across Three Core Business Segments

2020 was a challenging year for all industries! The pharmaceutical industry faced unprecedented challenges, having to withstand the impact of the COVID-19 pandemic on performance while enduring the growing pains associated with national policy adjustments.

Amid this severe situation, Mingyan Pharmaceutical has withstood numerous tests and recently successfully completedPre-Series A financing, with the company’s valuation exceeding RMB 100 million. This marks that Mingyan Pharma’s business model and growth potential have been recognized by both the industry and investors.

ExperienceIIIOver the years of development, Mingyan Pharma has evolved from its initial focus on clinical research services for bioequivalence studies into a provider of systematic lifecycle management solutions for pharmaceuticals, dedicated to delivering professional and efficient services to Chinese pharmaceutical enterprises.CRO Services: Empowering Chinese Pharmaceutical Companies to Build World-Class Drug R&D Systems.

According to Mingyan PharmaPresident/Mr. He Xiaobing, CEO, introduced that the company currently has three main business segments:

Since the former China Food and Drug Administration (CFDA) comprehensively launched the consistency evaluation of quality and efficacy for generic drugs, Mingyan Pharma has been committed to accelerating the R&D process of generic drugs. It provides professional and efficient international supply services of reference listed drugs (RLDs), impurities, and reference standards to the R&D departments of generic drug manufacturers. Meanwhile, Mingyan Pharma vigorously develops international supply resources for active pharmaceutical ingredients (APIs), helping Chinese generic drug companies import high-quality, affordable, and sufficiently supplied APIs, thereby effectively reducing the cost of generic drugs.

Mingyan Pharma’s business covers the entire drug R&D value chain: procurement of reference listed drugs and impurity reference standards, import of active pharmaceutical ingredients and excipients, pharmaceutical research, clinical trials, regulatory submissions, and market launch planning; it has its own professional teams both domestically and internationally, with in-depth familiarityGuidelines, laws, and regulations issued by the NMPA and CDE, combined with extensive international resources and project experience, provide robust technical support for projects. We offer diverse methodologies and approaches to address specific technical challenges encountered during R&D, manufacturing, and registration, ensuring successful project completion.

Mingyan Pharmaceutical aligns with the direction of China’s pharmaceutical industry reform, leverages the Marketing Authorization Holder (MAH) system, actively explores channels for integrating with international pharmaceutical resources, effectively alleviates the contradiction between high domestic drug production costs and low commercial value, and fundamentally addresses the issues faced by the general public due to drug pricing.“The Social Contradictions of ‘No Available Treatment’ and ‘Poverty Due to Illness’.”

In 2020, the impact of the newly revised Drug Administration Law continued to expand, the National Reimbursement Drug List underwent updates, and volume-based drug procurement became the norm. Under stricter conditions for R&D and market regulation, how to align with national policies, create clinical value, reduce production costs, and return to the fundamental mission of pharmaceutical manufacturing has become an imperative question for every pharmaceutical professional.

It is precisely for this reason thatThe successful completion of the pre-Series A financing holds particular significance for Mingyan Pharma. Moving forward, Mingyan Pharma will continue to strengthen its project management capabilities for the international R&D of generic drugs, increase R&D investment, and enhance service quality, contributing its strength to the rise of China’s pharmaceutical industry.